Pharvaris (PHVS) Consolidated Net Income (2020 - 2026)
Pharvaris (PHVS) reported Consolidated Net Income of -$45.6 million for Q1 2026, up 5.89% on a YoY basis from -$43.0 million in Q1 2025, and up 77.46% quarter-over-quarter from -$202.2 million in Q4 2025.
Pharvaris (PHVS) Consolidated Net Income (2020 - 2026) Analysis & Trends
Pharvaris has reported Consolidated Net Income for 7 years, with the latest figure at -$45.6 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income rose 5.89% year-over-year to -$45.6 million; the trailing twelve-month figure through Mar 2026 stood at -$342.7 million (down 111.85% YoY), and the FY2025 full-year result was -$198.5 million, down 36.64% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$45.6 million, up from -$202.2 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$10.5 million in Q2 2022, with the low at -$202.2 million in Q4 2025.
- Historically, Consolidated Net Income has averaged -$42.4 million across 5 years, with a median of -$34.4 million in 2023.
- Annual changes were most pronounced in 2022 — Consolidated Net Income jumped 42.41% — and 2025, when it plunged 464.49%.
- Pharvaris' Consolidated Net Income stood at -$39.7 million in 2022, then advanced by 13.23% to -$34.4 million in 2023, then fell by 4.04% to -$35.8 million in 2024, then sank by 464.49% to -$202.2 million in 2025, then jumped by 77.46% to -$45.6 million in 2026.
- The last three Consolidated Net Income figures came in at -$45.6 million (Q1 2026), -$202.2 million (Q4 2025), and -$43.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - | -45.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.57 Mn |
| Dec 31, 2025 | -202.21 Mn |
| Sep 30, 2025 | -43.63 Mn |
| Jun 30, 2025 | -51.25 Mn |
| Mar 31, 2025 | -48.43 Mn |
| Dec 31, 2024 | -35.82 Mn |
| Sep 30, 2024 | -45.55 Mn |
| Jun 30, 2024 | -31.94 Mn |
| Mar 31, 2024 | -30.13 Mn |
| Dec 31, 2023 | -34.43 Mn |
| Sep 30, 2023 | -25.53 Mn |
| Jun 30, 2023 | -23.74 Mn |
| Mar 31, 2023 | -24.23 Mn |
| Dec 31, 2022 | -39.68 Mn |
| Sep 30, 2022 | -10.98 Mn |
| Jun 30, 2022 | -10.54 Mn |
| Mar 31, 2022 | -17.94 Mn |
| Dec 31, 2021 | -14.14 Mn |
| Sep 30, 2021 | -10.70 Mn |
| Jun 30, 2021 | -18.30 Mn |